Company intelligence / Profile preview

Paths Innovation

United States

Ownership: Private
Development stage: Other

Overview

PATH Biotech uses an AI-powered platform (PATHTM) to identify and develop small molecule therapeutics for neurodegenerative, oncologic, auto-immune, and age-related disorders. Some programs have reached early clinical development, but no published pivotal clinical results as of May 2025.

Therapeutic areas: ImmunologyEndocrinologyNeurologyOtherOncology
Modalities: Small moleculeChemical drugs
Industry: Biotech

Beyond the preview

Go deeper on Paths Innovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paths Innovation.

Explore the full profile